« Back
Home /
Temsirolimus

Temsirolimus

Item no.	TMO-T2145-200mg
Manufacturer	TargetMol
CASRN	162635-04-3
Amount	200 mg
Quantity options	100 mg 1 mL x 10 mM (in DMSO) 10 mg 1 mg 1 mL 200 mg 25 mg 2 mg 500 mg 50 mg 5 mg
Category	Oncology Reagents & Chemicals Molecules By Organ Renal Cancer
Type	Molecules
Specific against	other
Citations	1. Shor B, et al. Y Res, 2008, 68(8), 2934-2943.
Smiles	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	NSC 683864,CCI-779
Shipping Condition	Cool pack
Available
Manufacturer - Targets	Apoptosis\|\|\|Autophagy\|\|\|mTOR
Shipping Temperature	Cool pack
Storage Conditions	-20
Molecular Weight	1030.29
Description	Temsirolimus (CCI-779) is a specific mTOR inhibitor ( IC50: 1.76 μM), used in the treatment of advanced renal cell cancer.
Pathways	Autophagy\|\|\|PI3K/Akt/mTOR signaling\|\|\|Apoptosis
Bioactivity	Temsirolimus is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the FDA in late May 2007, and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative of sirolimus and is sold as Torisel.
Receptor	mTOR

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

TMO-T2145-200mg-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 200 mg

available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question